Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

Results of the Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer to be presented at 2023 ASCO Genitourinary Cancers Symposium (ASCO GU)

Related Keywords

Germany ,United States ,Munich ,Bayern ,Texas ,San Francisco ,California ,Scintomics Gmb ,Brianf Chapin , ,University Of Texas Md Anderson Cancer Center ,Study Group ,Division Of Surgery ,Technical University Of Munich ,Duke University Medical Center ,Department Of Urology ,Blue Earth Diagnostic Medical Affairs ,Blue Earth Diagnostics ,Cancers Symposium ,Prostate Specific Membrane Antigen Targeted ,Emission Tomography ,Advanced Prostate Cancer ,Associate Professor ,Cancer Center ,Prostate Cancer ,Earth Diagnostics ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Scintomics Gmbh ,